Literature DB >> 32972733

Endometrial thickness after ovarian stimulation with gonadotropin, clomiphene, or letrozole for unexplained infertility, and association with treatment outcomes.

Alexander M Quaas1, Sarah Z Gavrizi2, Jennifer D Peck2, Michael P Diamond3, Richard S Legro4, Randal D Robinson5, Peter Casson6, Gregory M Christman7, Heping Zhang8, Karl R Hansen2.   

Abstract

OBJECTIVE: To study the association of endometrial thickness (EMT) with live birth rates (LBR) in ovarian stimulation with intrauterine insemination (OS-IUI) treatments for unexplained infertility.
DESIGN: Prospective cohort analysis of the Reproductive Medicine Network's Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation (AMIGOS) randomized controlled trial.
SETTING: Multicenter randomized controlled trial. PATIENTS: A total of 868 couples with unexplained infertility (n=2,459 cycles).
INTERVENTIONS: OS-IUI treatment cycles (n = 2,459) as part of the AMIGOS clinical trial. MAIN OUTCOME MEASURES: Live birth rates; unadjusted and adjusted risk ratios (RR) for live birth by EMT category, calculated using generalized estimating equations.
RESULTS: The overall mean EMT on day of human chorionic gonadotropin administration in cycles with a live birth was significantly greater than in those without. Compared to the referent EMT group of 9 to 12 mm, the unadjusted RR for live birth for the EMT groups of ≤5 and 6-8 were 0.48 and 0.92, respectively. The test for trend indicated evidence of decreasing LBR with decreasing EMT. After adjustment for ovarian stimulation medication, a linear trend was no longer supported. Stratified analyses revealed no differences in associations by treatment group.
CONCLUSIONS: In OS-IUI for unexplained infertility, higher LBR are observed with increasing EMT; however, EMT is not significantly associated with LBR when adjusted for OS treatment type. Appreciable LBR are seen at all EMT, even those of ≤5 mm, suggesting that OS-IUI cycles should not be canceled for thin endometrium. CLINICAL TRIAL REGISTRATION NUMBER: NCT01044862.
Copyright © 2020 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Unexplained infertility; endometrial thickness; intrauterine insemination; live birth; ovarian stimulation

Mesh:

Substances:

Year:  2020        PMID: 32972733      PMCID: PMC7796980          DOI: 10.1016/j.fertnstert.2020.07.030

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  3 in total

1.  Assessment of Knowledge, Attitude, and Practice of Obstetricians and Gynecologists Toward Off-Label Medicine Use in Female Reproductive Health Issues.

Authors:  Sadia Shakeel; Wajiha Iffat; Ambreen Qamar; Shagufta Nesar; Fareeha Butt; Sobia Naseem Siddiqui; Hina Rehman; Anees Ur Rehman
Journal:  Front Public Health       Date:  2022-03-24

Review 2.  The Treatment of Complementary and Alternative Medicine on Female Infertility Caused by Endometrial Factors.

Authors:  Jing Lin; Haoyue Ma; Hang Li; Jing Han; Tingting Guo; Zhen Qin; Liyan Jia; Yuehui Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-07       Impact factor: 2.650

Review 3.  Letrozole for Female Infertility.

Authors:  Ai-Min Yang; Na Cui; Yi-Fei Sun; Gui-Min Hao
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-16       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.